Aura Biosciences, Inc.
AURA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | -0.46 | -0.17 | -2.16 |
| FCF Yield | -5.73% | -8.01% | -5.94% | -3.53% |
| EV / EBITDA | -10.27 | -10.08 | -14.36 | -19.03 |
| Quality | ||||
| ROIC | -14.63% | -19.82% | -16.30% | -12.02% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.77 | 0.85 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 11.59% | 2.92% | -55.32% | 6.24% |
| Safety | ||||
| Net Debt / EBITDA | 3.35 | 0.73 | 0.47 | 0.28 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -385.80 | -620.41 | -334.99 | -572.49 |